Pricing Log in Create free account

Mineralys Therapeutics, Inc. (MLYS) vs Palvella Therapeutics, Inc. (PVLA)

Mineralys Therapeutics, Inc. and Palvella Therapeutics, Inc. are both Biotechnology companies. Mineralys Therapeutics, Inc. and Palvella Therapeutics, Inc. are of similar size ($1.9B and $1.8B). Across the 9 metrics below, Palvella Therapeutics, Inc. leads on 7 and Mineralys Therapeutics, Inc. on 2.

Valuation

Metric MLYS PVLA Biotechnology median
P/E n/m n/m 8.50
P/S n/m 41.55 9.71
P/B 3.12 7.96 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 35.55 9.21
Earnings yield (20.89%) (4.01%) (33.15%)
Free cash flow yield (8.07%) (1.86%) (25.50%)

Profitability

Metric MLYS PVLA Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (80.88%) (46.63%) (56.36%)
Return on assets (69.67%) (37.70%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MLYS PVLA Biotechnology median
Revenue growth (TTM) — 146.67% 6.02%
EPS growth (last fiscal year) 37.43% 52.62% 30.26%
Revenue growth, 5-year CAGR — 8.03% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MLYS PVLA Biotechnology median
Debt to equity 0.18 0.00 0.00
Current ratio 34.46 21.18 4.72
Net debt to EBITDA 3.85 1.50 0.96

Dividend

Metric MLYS PVLA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MLYS PVLA Biotechnology median
Market cap 1.91b 1.83b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack